MSD, Taiho to Wind Up Keytruda Copromotion at Year-End

MSD and Taiho Pharmaceutical will terminate their copromotion deal for the US giant’s anti-PD-1 antibody Keytruda (pembrolizumab) at the end of December, putting an end to nearly three years of their collaboration as the drug enjoys strong market penetration in...read more